About Kopran Laboratories Limited
Data last updated: 07 February 2026
Kopran Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in chemical distribution and retail, a part of the broader chemicals and materials sector. Incorporated on 12 August 1986, the company has been in operation for over 40 years.
Registered with ROC Mumbai under CIN U24230MH1986PLC040602.
Capital: an authorised share capital of ₹8 Cr and a paid-up capital of ₹5.3 Cr. Formerly known as Kopran Laboratories Private Limited. It is led by directors including Surendran Nair and Adarsh Rajendra Somani.
Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: Parijat House1076 Dr E Moses Rd Worli, Mumbai, Maharashtra, India – 400018.
As per the financials filed for FY 2025, the company reported a revenue of ₹112.82 Cr, a growth of 9% compared to the previous year.
The company has a workforce of approximately 59 employees as per the latest available data.
The company is associated with 1 brand - Kopran. As per MCA filings, the company has open charges of ₹52.24 Cr and satisfied charges of ₹45.24 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kopranlaboratories.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressParijat House1076 Dr E Moses Rd Worli, Mumbai, Maharashtra, India – 400018
-
IndustryChemicals and Materials, Chemical Distribution & Retail
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Kopran Laboratories Limited
Kopran Laboratories Limited has one previous CIN (Corporate Identification Number): U24230MH1986GAP040602. The current CIN is U24230MH1986PLC040602, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230MH1986PLC040602 | Current |
| U24230MH1986GAP040602 | Previous |
Associated Brands with Kopran Laboratories Limited
Kopran Laboratories Limited operates one associated brand: Kopran. These brands represent Kopran Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical Company manufacturing a range of products | kopran.com |
Competitors & Alternatives of Kopran Laboratories Limited
Brands and companies operating in the same space as Kopran Laboratories Limited include Concord Biotech, Almac Group, Indoco Remedies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Kopran Laboratories Limited
Kopran Laboratories Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Kopran Laboratories Limited
Kopran Laboratories Limited is audited by KHANDELWAL JAIN & CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| KHANDELWAL JAIN & CO. | blur-value | blur-value | blur-value |
Board of Directors of Kopran Laboratories Limited
Kopran Laboratories Limited is currently managed by 5 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Surendran Nair | Director | 02 Aug 2024 | 1 Years 11 Months | Current |
| Adarsh Rajendra Somani | Director | 01 Sep 2015 | 10 Years 10 Months | Current |
|
Rajiv Bafna Tejraj
Also directs:
Sarvamangal Marcantile Company Limited
|
Director | 02 Aug 2024 | 1 Years 11 Months | Current |
| Varun Surendra Somani | Managing Director | 01 Sep 2015 | 10 Years 10 Months | Current |
|
Namrata Varun Somani
Also directs:
Sorabh Trading Private Limited, Apurva Caplease And Finance Private Limited, Panorama Finvest Pvt Ltd and 2 more
|
Director | 12 Feb 2015 | 11 Years 4 Months | Current |
Financials of Kopran Laboratories Limited FY 2025 filings available
Kopran Laboratories Limited reported revenue of ₹112.82 Cr (up 9% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Kopran Laboratories Limited
As of FY 2023, Kopran Laboratories Limited's shareholding pattern shows 90.44% by promoters, 9.56% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Kopran Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2025 | Others | ₹2.38 Cr | Open |
| 24 Sep 2025 | Yes Bank Limited | ₹71.15 Lakh | Open |
| 31 Jul 2025 | Yes Bank Limited | ₹1.21 Cr | Open |
| 26 Sep 2024 | Others | ₹22 Cr | Open |
| 05 Aug 2024 | Others | ₹1.12 Cr | Open |
Total charge records: 28 View all charges
Employees and EPFO Compliance at Kopran Laboratories Limited
Kopran Laboratories Limited has a workforce of 59 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Kopran Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Kopran Laboratories Limited
GSTIN & GST Filing Data of Kopran Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Kopran Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Kopran Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Kopran Laboratories Limited
MSME Payment Delays by Kopran Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Kopran Laboratories Limited
Subsidiaries & Group Companies of Kopran Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Kopran Laboratories Limited with ownership details.
MCA Filings & Documents of Kopran Laboratories Limited
MCA Filings & Documents of Kopran Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Kopran Laboratories Limited
Frequently Asked Questions about Kopran Laboratories Limited
Kopran Laboratories Limited is an active public limited company in the chemicals and materials sector based in Mumbai, Maharashtra, India. It was incorporated on 12 August 1986 (40+ years old) and is registered under CIN U24230MH1986PLC040602. The company has 59 employees.
Kopran Laboratories Limited reported revenue of ₹112.82 Cr for FY 2025 (up 9.00% YoY).
The current directors of Kopran Laboratories Limited are:
The primary industry of Kopran Laboratories Limited is chemicals and materials. The company specifically operates in chemical distribution and retail. The company is currently active in this sector.
Kopran Laboratories Limited can be reached at the registered office: Parijat House1076 Dr E Moses Rd Worli, Mumbai, Maharashtra, India – 400018, or through the website kopranlaboratories.com.
The authorised capital is ₹8 Cr, and the paid-up capital is ₹5.3 Cr.